IMI AMR Accelerator
  • ABOUT
    • AMR
    • Participants
  • PROJECTS
    • AB-Direct
    • COMBINE
    • ERA4TB
    • GNA NOW
    • PrIMAVeRa
    • RespiriNTM
    • RespiriTB
    • TRIC-TB
    • UNITE4TB
  • RESULTS
    • Project Portfolio
    • Publications
    • Public Webinars
    • Tools and Resources
  • NEWS
    • Latest news
    • Interviews
    • Newsletters
    • From partners
  • EVENTS
  • CONTACT
  • Menu Menu
Link to: RespiriNTM
Link to: RespiriTB
Link to: COMBINE
Link to: TRIC-TB
Link to: GNA NOW
Link to: ERA4TB
Link to: AB-Direct
Follow a manual added link

The AMR Accelerator


98

Participants

489

M€ Budget

9

Projects

13

Programmes in the Portfolio


The AMR Accelerator is an IMI Programme that comprises 9 projects with the shared goal of progressing the development of new medicines to treat or prevent resistant bacterial infections.

The AMR Accelerator aims to deliver up to 10 new preclinical candidates and 5 Phase II-ready assets by 2025.


With a wide-ranging series of antibacterial programmes the AMR Accelerator will enhance the overall pipeline of antibiotics to treat infections with M. tuberculosis, nontuberculous mycobacteria (NTM) and Gram-negative bacteria.

The AMR Accelerator is composed of three Pillars:

A Capability Building Network (the COMBINE and PrIMAVeRa projects) provides coordination and support across the Accelerator, and in addition has scientific goals to improve and standardise the animal models used in AMR research, and optimise clinical trial designs.

The Tuberculosis Drug Development Network (encompassing the ERA4TB and UNITE4TB projects) is working to accelerate the discovery of new combinations of drugs to treat tuberculosis.

The Portfolio Building Networks (the RespiriTB, RespiriNTM, TRIC-TB, GNA NOW and AB-Direct projects) support collaborative efforts to discover, develop and advance new and innovative antibacterial assets.

Learn more about the Accelerator Projects

Link to: AB-Direct

AB-Direct

  • 7 participants
  • > 3.7 M€ budget
  • 3 years. Started 1 July 2019

Antibiotic distribution and recovery in tissue

Read more

Link to: COMBINE

COMBINE

  • 11 participants
  • 25 M€ budget
  • 6 years. Started 1 Nov 2019

Coordinate the AMR Accelerator projects
Research to strengthen scientific basis in the AMR field

Read more

Link to: ERA4TB

ERA4TB

  • 32 participants
  • > 207 M€ budget
  • 6 years. Started 1 Jan 2020

Development of anti-TB drug combinations

Read more

Link to: GNA NOW

GNA NOW

  • 12 participants
  • > 31 M€ budget
  • 6 years. Started 1 July 2019

New antibiotics to treat Gram-negative infections

Read more

Link to: RespiriNTM

RespiriNTM

  • 9 participants
  • > 8 M€ budget
  • 6 years. Started 1 May 2019

Novel assets for non-tuberculous mycobacteria

Read more

Link to: RespiriTB

RespiriTB

  • 9 participants
  • > 9.9 M€ budget
  • 6 years. Started 1 May 2019

New assets for multidrug-resistant tuberculosis

Read more

Link to: TRIC-TB

TRIC-TB

  • 2 participants
  • > 8.3 M€ budget
  • 4 years. Started 1 May 2019

Define a new place for Ethionamide in 1st-line TB treatments

Read more

Follow a manual added link

UNITE4TB

  • 29 participants
  • 185 M€ budget
  • 7 years. Started 1 June 2021

Accelerate the development of new treatment regimens for tuberculosis

Read more

AMR ACCELERATOR NEWSLETTER

– November 2021

Stay up-to-date with the AMR Accelerator!

Follow us:

The AMR Accelerator has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreements No 853967 I 853989 I 853979 I 853932 I 853800 I 853903 I 853976. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. ERA4TB receives additional support from Global Alliance for TB Drug Development, Bill & Melinda Gates Foundation and University of Dundee. UNITE4TB receives additional support from Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research.

https://www.imi.europa.eu/



© BIOCOM Interrelations GmbH
  • LinkedIn
  • Youtube
  • Contact
  • Imprint
  • Privacy Statement
  • Disclaimer
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

DenyAccept allConfigure

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Google Webfont Settings:

Vimeo and Youtube video embeds:

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, you cannot refuse them without impacting how our site functions. You can block or delete them by changing your browser settings and force blocking all cookies on this website.

Other external services

We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Statement
Accept settingsHide notification only
Open Message Bar